BIOMAT Database Logo BIOMAT Database Logo

Surfactant Metabolism Dysfunction and Childhood Interstitial Lung Disease (chILD). 2009

Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Royal Belfast Hospital for Sick Children, Queens University Belfast, Grosvenor Road, Belfast BT12 6BA, UK.

Surfactant deficiency and the resultant respiratory distress syndrome (RDS) seen in preterm infants is a major cause of respiratory morbidity in this population. Until recently, the contribution of surfactant to respiratory morbidity in infancy was limited to the neonatal period. It is now recognised that inborn errors of surfactant metabolism leading to surfactant dysfunction account for around 10% of childhood interstitial lung disease (chILD). These abnormalities can be detected by blood sampling for mutation analysis, thereby avoiding the need for lung biopsy in some children with chILD.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011663 Pulmonary Surfactants Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI. Surfactants, Pulmonary,Pulmonary Surfactant,Surfactant, Pulmonary
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006819 Hyaline Membrane Disease A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS). Disease, Hyaline Membrane,Diseases, Hyaline Membrane,Hyaline Membrane Diseases
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D017563 Lung Diseases, Interstitial A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features. Diffuse Parenchymal Lung Disease,Diffuse Parenchymal Lung Diseases,Interstitial Lung Disease,Interstitial Lung Diseases,Pneumonia, Interstitial,Pneumonitis, Interstitial,Interstitial Pneumonia,Interstitial Pneumonias,Interstitial Pneumonitides,Interstitial Pneumonitis,Lung Disease, Interstitial,Pneumonias, Interstitial,Pneumonitides, Interstitial

Related Publications

Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
chILD - Childhood Interstitial Lung Disease.
April 2023, Archives of disease in childhood,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Surfactant protein disorders in childhood interstitial lung disease.
September 2021, European journal of pediatrics,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Surfactant dysfunction mutations in children's interstitial lung disease and beyond.
October 2005, American journal of respiratory and critical care medicine,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Surfactant lipidomics in healthy children and childhood interstitial lung disease.
January 2015, PloS one,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Childhood Interstitial Lung Disease (chILD): shining a new light on childhood!
August 2022, Thorax,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Clinical and research innovations in childhood interstitial lung disease (chILD).
April 2024, Pediatric pulmonology,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Advances in Imaging of the ChILD - Childhood Interstitial Lung Disease.
November 2022, Radiologic clinics of North America,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Childhood Interstitial Lung Disease.
March 2023, Pediatric allergy, immunology, and pulmonology,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Child Interstitial Lung Disease in an Infant with Surfactant Protein C Dysfunction due to c.202G>T Variant (p.V68F).
February 2022, Lung,
Lynne McFetridge, and Aoife McMorrow, and Patrick J Morrison, and Michael D Shields
Surfactant proteins in pediatric interstitial lung disease.
January 2016, Pediatric research,
Copied contents to your clipboard!